Earnings ·
McKesson raises full-year adjusted EPS guidance to $44.20–$45.00 after Q1 revenue rose 8% to $105.4 billion
MCKMcKesson Corp
McKesson Corporation reported preliminary results for the fiscal 2027 first quarter ended June 30, 2026. Consolidated revenues increased 8% to $105.4 billion, driven by growth in North American Pharmaceutical and Oncology & Multispecialty segments. Adjusted earnings per diluted share rose 20% to $9.93, while GAAP earnings per diluted share decreased 18% to $5.15 due to a $293 million redemption value adjustment for redeemable non-controlling interests. The company raised its full-year adjusted EPS guidance to $44.20–$45.00 from the previous range of $43.80–$44.60. McKesson returned $2.6 billion to shareholders, including $2.5 billion in stock repurchases and a 15% dividend increase to $0.94 per share. Additionally, the company announced the name Wellverse for its planned separated Medical-Surgical Solutions business and completed a $1.25 billion minority interest sale of that segment to Apollo Funds. McKesson Corporation operates as a diversified healthcare services leader providing pharmaceutical distribution, biopharma services, and medical-surgical solutions.